BACKGROUND: Schizophrenia is a serious mental illness, the pharmacological treatment of which comprises primarily the use of antipsychotics. However, non-adherence to their use and its reliable determination present a serious clinical and economic problem. This study aimed to determine therapeutic adherence in outpatients with schizophrenia spectrum disorders by combining short-term electronic monitoring of dispenser opening with the measurement of antipsychotic blood concentrations. METHODS: A total of 55 patients underwent a week-long electronic monitoring of dispenser opening and measurement of blood concentrations before and after monitoring. Patients who correctly opened the dispenser at least in 80% of scheduled time points during the weekly interval and, at the same time, did not show a change in blood concentration of the antipsychotic by more than 30% in any direction, were considered adherent. RESULTS: 69.1% of the patients met the adherence criteria, which was less than that determined by the Drug Attitude Inventory (DAI-10), the Visual Analogue Scale (VAS), and the Clinician Rating Scale (CRS). 7.3% of the patients took less than 80% of the prescribed doses and a change in blood concentrations of the antipsychotic by more than 30% was detected in 25.4% of the patients. In 70.9% of patients, the detected concentrations were within the recommended therapeutic reference interval. The groups of adherent and non-adherent patients did not differ statistically significantly in the severity of their illness as determined by the Clinical Global Impression (CGI), the Personal and Social Performance scale (PSP), and the Positive and Negative Syndrome Scale (PANSS). CONCLUSIONS: The combined method of evaluating adherence in schizophrenia patients confirmed the results determined by other methods. The benefits of this approach are described in the paper.

Department of Clinical Neurosciences Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Clinical Pharmacology Institute of Laboratory Medicine University Hospital Ostrava Ostrava Czech Republic

Department of Cybernetics and Biomedical Engineering Faculty of Electrical Engineering and Computer Science VSB Technical University Ostrava Ostrava Czech Republic

Department of Psychiatry University Hospital Ostrava 17 listopadu 1790 Ostrava Poruba 708 52 Czech Republic

Institute of Clinical Pharmacology Faculty of Medicine University of Ostrava Ostrava Czech Republic

See more in PubMed

Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet Lond Engl. 2019;394(10202):939–51. PubMed PMC

Takeuchi H, Kantor N, Sanches M, Fervaha G, Agid O, Remington G. One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. Br J Psychiatry J Ment Sci. 2017;211(3):137–43. PubMed

Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, et al. Real-World effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–93. PubMed PMC

Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1–46. quiz 47–8. PubMed

Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892–909. PubMed

Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171–80. PubMed PMC

Misdrahi D, Tessier A, Husky M, Lange AC, Vrijens B, Llorca PM, et al. Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS®): A six-month post-discharge prospective study. Schizophr Res. 2018;193:114–8. PubMed

Sacchetti E, Vita A. Poor Adherence to Antipsychotic Medication in People with Schizophrenia: Diffusion, Consequences and Contributing Factors. In: Sacchetti E, Vita A, Siracusano A, Fleischhacker W, editors. Adherence to Antipsychotics in Schizophrenia [Internet]. Milano: Springer Milan; 2014 [cited 2024 Apr 7]. pp. 1–84. Available from: 10.1007/978-88-470-2679-7_1

Sabaté EWHO. Adherence to Long-Term Therapies: Evidence for Action, 2003 - PAHO/WHO| Pan American Health Organization [Internet]. World Health Organization; 2003 [cited 2024 Apr 7]. Available from: https://www.paho.org/en/documents/who-adherence-long-term-therapies-evidence-action-2003

Kikkert MJ, Barbui C, Koeter MWJ, David AS, Leese M, Tansella M, et al. Assessment of medication adherence in patients with schizophrenia: the Achilles heel of adherence research. J Nerv Ment Dis. 2008;196(4):274–81. PubMed

Yaegashi H, Kirino S, Remington G, Misawa F, Takeuchi H. Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: A systematic review and Meta-analysis. CNS Drugs. 2020;34(6):579–98. PubMed

Velligan DI, Lam YWF, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006;32(4):724–42. PubMed PMC

Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177–83. PubMed

Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry J Ment Sci. 1998;172:413–9. PubMed

Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76. PubMed

Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–9. PubMed

Guy W. ECDEU assessment manual for psychopharmacology. Rev. 1976. Rockville, Md: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. 603 p.

Uřinovská R, Brozmanová H, Sištík P, Silhán P, Kacířová I, Lemr K, et al. Liquid chromatography-tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;907:101–7. PubMed

Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–02):9–62. PubMed

Lieberman E, by JA MD, Stroup TS, Perkins MPH, Dixon DO. and LB. The American Psychiatric Association Publishing Textbook of Schizophrenia. Revised edition. Lieberman JA, Dixon LB, editors. Washington, D.C: Amer Psychiatric Pub Inc; 2019. 320 p.

Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006;67(Suppl 5):3–8. PubMed

Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv Wash DC. 2007;58(9):1187–92. PubMed

Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res. 2007;90(1–3):229–37. PubMed

Yang J, Ko YH, Paik JW, Lee MS, Han C, Joe SH, et al. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Schizophr Res. 2012;134(2–3):226–31. PubMed

Acosta FJ, Ramallo-Fariña Y, Bosch E, Mayans T, Rodríguez CJ, Caravaca A. Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®). Schizophr Res. 2013;146(1–3):196–200. PubMed

Brain C, Sameby B, Allerby K, Lindström E, Eberhard J, Burns T, et al. Twelve months of electronic monitoring (MEMS®) in the Swedish COAST-study: a comparison of methods for the measurement of adherence in schizophrenia. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2014;24(2):215–22. PubMed

Sendt KV, Tracy DK, Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015;225(1–2):14–30. PubMed

Yang M, Barner JC, Worchel J. Factors related to antipsychotic oversupply among central Texas veterans. Clin Ther. 2007;29(6):1214–25. PubMed

Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40(8):630–9. PubMed

Silhan P, Urinovska R, Kacirova I, Hyza M, Grundmann M, Ceskova E. What does antidepressant drug level monitoring reveal about outpatient treatment and patient adherence?? Pharmacopsychiatry. 2019;52(2):78–83. PubMed

Lin D, Thompson-Leduc P, Ghelerter I, Nguyen H, Lafeuille MH, Benson C, et al. Real-World evidence of the clinical and economic impact of Long-Acting injectable versus oral antipsychotics among patients with schizophrenia in the united States: A systematic review and Meta-Analysis. CNS Drugs. 2021;35(5):469–81. PubMed PMC

Solmi M, Tiihonen J, Lähteenvuo M, Tanskanen A, Correll CU, Taipale H. Antipsychotics use is associated with greater adherence to cardiometabolic medications in patients with schizophrenia: results from a nationwide, within-subject design study. Schizophr Bull. 2022;48(1):166–75. PubMed PMC

Milz R, Benson C, Knight K, Antunes J, Najarian D, Lopez Rengel PM, et al. The effect of longer dosing intervals for Long-Acting injectable antipsychotics on outcomes in schizophrenia. Neuropsychiatr Dis Treat. 2023;19:531–45. PubMed PMC

Wickström G, Bendix T. The Hawthorne effect--what did the original Hawthorne studies actually show? Scand J Work Environ Health. 2000;26(4):363–7. PubMed